Invion Limited has appointed Dr. Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers Research Group at Hudson Institute of Medical Research, to its advisory board. Dr. Stephens is regarded as one of Australia's foremost experts in the field of ovarian cancer research. He is Research Fellow at the Ovarian Cancer Research Foundation (OCRF) and a Senior Research Affiliate (Honorary) with Epworth Healthcare. Dr. Stephens established the ovarian cancer biomarker group at Hudson Institute in 2009 after completing his PhD in the Department of Biochemistry at Monash University and undertaking a postdoctoral position at the University of Sydney using proteomics to discover novel antibiotic targets in bacteria.